It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study , (December 18, 2023)
Retatrutide's dosing protocol typically involves gradual escalation starting from 2 mg weekly, increasing by 2-4 mg increments every 4 weeks until the target maintenance dose is achieved
This approach conserves peptide while maintaining baseline healing support
GIPR activation also influences lipid metabolism and adipose tissue function
But they are rat studies, and the specific outcomes were not always clearly quantified even within those